

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 September 2020 (10.09.2020)



(10) International Publication Number
WO 2020/180864 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) C07K 14/54 (2006.01)
A61K 35/763 (2015.01) C07K 14/52 (2006.01)

(21) International Application Number:

PCT/US2020/020793

(22) International Filing Date:

03 March 2020 (03.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/813,961 05 March 2019 (05.03.2019) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **DEVOSS, Jason James**; c/o Amgen Inc., One Amgen Center Drive, Legal Dept - Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **MEISEN, Walter Hans**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **TINBERG, Christine Elaine**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **COOKE, Kee-gan**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, Mail Stop 28-5-A, Thousand Oaks, Cal-

ifornia 91320-1799 (US). **MOESTA, Achim Klaus**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).


(74) Agent: **RAYMOND, Doss M.**; c/o Amgen Inc., One Amgen Center Drive, Law Dept - Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: USE OF ONCOLYTIC VIRUSES FOR THE TREATMENT OF CANCER

FIG. 1



(57) Abstract: The present invention relates to the use of oncolytic viruses (e.g., modified HSV-1 viruses) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*